A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The study will last approximately 35 weeks.
Epistemonikos ID: 91f714a5499c50a5010b4a9b8a050546598d93d6
First added on: Apr 23, 2026